- Trial phase
- Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
- Time to market
- Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
- Why 4/10
- ZYNLONTA is already approved and generating commercial revenue, so there is no pending PDUFA or pivotal readout that represents a single binary event for the stock. The next hard catalyst is the ASH 2026 data presentations (December 5-8, 2026), but these are data updates, not a regulatory decision. The Japan filing decision and the FDA path to full approval are important but lack dated timelines. Per the impact score rubric, an approved drug with no imminent new regulatory decision scores 3-5; this is set at 4 reflecting that ZYNLONTA is the company's only product and drives the entire thesis, but no binary catalyst is scheduled within 6 months.
Watch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.
Price Chart
Executive Summary
ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate that received FDA accelerated approval in 2021 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy. It is the only marketed product of ADC Therapeutics (NYSE: ADCT), a commercial-stage Swiss biotech. The drug generated $21M in Q3 2026 net product revenue (up 33% YoY), the fourth straight quarterly beat. However, the confirmatory Phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) posted a 13% death rate in June 2026, sending shares down ~50% and prompting the FDA to cite significant safety concerns. The company is now evaluating an alternative regulatory path for full approval while advancing earlier-line combination studies (LOTIS-7 with bispecific antibodies). A financial restructuring in October 2026, including an $86.6M PIPE, extended the cash runway into 2029.
How It Works
ZYNLONTA is an antibody-drug conjugate (ADC) that works like a guided missile. The antibody portion targets CD19, a protein found on the surface of B-cell lymphoma cells. Once bound, the drug releases a toxic payload (a pyrrolobenzodiazepine dimer) that kills the cancer cell. It is given as an intravenous infusion.
Trial Status
ZYNLONTA is FDA-approved under accelerated approval for third-line+ relapsed/refractory DLBCL. The confirmatory Phase 3 LOTIS-5 trial (ZYNLONTA + rituximab vs. standard chemo) reported topline data in June 2026 showing elevated deaths (13% in the study arm), leading the FDA to cite significant concerns. The company is evaluating an alternative regulatory path. LOTIS-7 (Phase 1b, ZYNLONTA + bispecific antibody mosunetuzumab) completed enrollment in June 2026 with encouraging initial safety data. Multiple abstracts accepted for the 68th ASH Annual Meeting in December 2026. A Japan marketing authorization application was filed by partner Tanabe Pharma in October 2026.
The Two-Sided Case
Upcoming Catalysts
- 68th ASH Annual Meeting (December 5-8, 2026): Multiple ZYNLONTA abstracts including LOTIS-7 combination data and potentially full LOTIS-5 results
- Japan marketing authorization decision by Ministry of Health, Labor and Welfare (filed October 29, 2026 by partner Tanabe Pharma)
- FDA regulatory path update: Company evaluating alternative path to full approval after pre-sBLA meeting
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ADC Therapeutics SA S-3 ADCT ·Originating report